Clinical Trial Search

Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization — 28; 14 Participants

Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants

Primary: Response Rate — .125 proportion of participants

Primary: Objective Response (Complete and Partial) Evaluated Using RECIST Criteria — 0 participants

Primary: Overall Survival (OS) — 5.4; 6.5 months — p=0.28

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Overall Survival Rate at 6 Months — 58 percentage of participants

Primary: Percentage of Patients in Non-progression at 2 Months — 14.3 percentage of participants

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Overall Survival — 8.8; 9.8 months — p=0.72

Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026

Primary: 12- Month Overall Survival (OS) — 16 Participants

Primary: Progression-free Survival — 3.9 months

Primary: Time to Tumor Progression — 3.5 months

Primary: Overall Survival — 4.2; 8.3 months — p=0.36

Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants

Primary: Six Month Survival Rate — 25; 67; 33 percentage of patients

Primary: Maximum Tolerated Dose (MTD) of Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-stabilized Nanoparticle Formulation Combination (Phase Ib) — 80 milligrams

Primary: Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects — 2 Participants — p=0.824

Primary: Overall Response Rate (ORR) — 6.9 percentage of participants

Primary: Overall Survival — 6.4; 5.9 months

Primary: Progression-free Survival — 5.7 months

Primary: Maximum Tolerated Dose (MTD) of Epacadostat — 600 mg BID

Primary: Number of Participants With Progressive Disease, — 2 Participants

Primary: Treatment Response — 0; 0; 0; 0 participants

Primary: Overall Survival (OS) — 7.5; 6.7 months

Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients

Primary: Maximum Tolerated Dose Determination — 6 mg/kg IMC-A12

Primary: The Percentage of Untreated and Previously Treated Patients That Had a Partial Response to Treatment — 40; 7.1 percentage of patients

Primary: Objective Response Rate (ORR) During the Combination Therapy Phase — 29.2; 35.2; 46.3; 0 percentage of patients